www.medscape.

com

Importance and Management of Chronic Sleep Apnoea in Cardiology

Leeor M. Jaffe, John Kjekshus, Stephen S. Gottlieb Eur Heart J. 2013;34(11):809-815.

Abstract and Introduction

Abstract

Sleep apnoea is a common, yet underestimated, chronic disorder with a major impact on morbidity and mortality in the general population. It is quickly becoming recognized as an independent risk factor for cardiovascular impairment. Hypertension, coronary artery disease, diabetes, cardiovascular rhythm and conduction abnormalities, cerebrovascular disease, and heart failure have all been linked to this syndrome. This review will explore the critical connection between sleep apnoea and chronic cardiovascular diseases while highlighting established and emerging diagnostic and treatment strategies.
Introduction

Sleep apnoea is a common, yet underestimated, chronic disorder with a major impact on morbidity and mortality in the general population. It is quickly becoming recognized as an independent risk factor for cardiovascular impairment. Hypertension, coronary artery disease (CAD), diabetes, cardiovascular rhythm and conduction abnormalities, cerebrovascular disease, and heart failure (HF) have all been linked to this syndrome. This review will explore the critical connection between sleep apnoea and chronic cardiovascular diseases while highlighting established and emerging diagnostic and treatment strategies.

Classification
Sleep apnoea describes a syndrome of nocturnal respiratory interruptions resulting in sleep fragmentation, daytime hypersomnolence, and oxyhaemoglobin desaturation, usually unrecognized by the patient. [1] The severity of sleep apnoea is commonly quantified by the apnoea-hypopnoea index (AHI), which is the number of apnoeic and hypopnoeic events per hour. An AHI of 515 indicates mild disease, 1530 indicates moderate disease, and >30 indicates severe disease. The prevalence of sleep apnoea in the general population appears surprisingly high, even when bias is taken into account in both the selection of subjects referred for sleep studies and their willingness to participate. Sleep apnoea, of any degree, was reported to be present in 17% of adults according to one study, and moderate to severe sleep apnoea (AHI 15) in 5.7%.[2] Other studies found the prevalence of moderate sleep apnoea to be between 1 and 14%. It is reasonable to assume that ~1 in 5 adults has at least mild sleep apnoea, and 1 in 15 adults has at least moderate sleep apnoea. [3] The sleep apnoea syndrome can be divided into obstructive sleep apnoea (OSA), central sleep apnoea (CSA), and the combination of the two. Obstructive sleep apnoea is caused by nocturnal upper airway collapse with preserved breathing efforts during apnoea. The risk of OSA rises with increasing body weight; active smoking; diabetes; age; and influence of alcohol, sedatives, and muscle relaxants.[4] Central sleep apnoea, also clinically known as Cheyne-Stokes respiration, is a result of decreased ventilatory drive, mainly due to loss of fine tuning of the breathing control system. It is especially common in patients with heart failure or stroke when the voluntary respiratory control is disabled during sleep.[5] Patients with CSA have enhanced chemoreceptor sensitivity.[6] Relatively minor increases in nocturnal PaCO2 can cause an exaggerated hyperventilatory response, often driving PaCO2 below the apneoic threshold. The resulting apnoea causes CO2 to build up, perpetuating the cycle. A prolonged circulation time may further delay chemoreceptor response to hypoxia and hypercapnia, further desynchronizing the circulatory, respiratory, and neurological systems [7] (Figure 1).

Figure 1.

Mechanisms leading to the development and propagation of central sleep apnoea. Deregulation of the pulmonary and nervous systems lead to haemodynamic derangements, hypoxia, and hypercapnoea. 147 Some patients have both types of respiratory sleep disorder. They are, for the most part, patients with longstanding OSA or heart failure who have developed chronic malfunctioning of the respiratory regulatory system.[1]

Pathophysiology of Chronic Sleep Apnoea

Patients with sleep apnoea suffer a host of haemodynamic and biochemical derangements. [8] Obstructive sleep apnoea causes sharp decreases in intrathoracic pressure which increases venous return, results in an acute leftward intraventricular septal shift, alters transmural cardiac pressures, impairs left ventricular filling, increases

myocardial oxygen demand,[9] and causes ischaemia.[10] In addition, haemodynamic derangements and the stress of frequent awakenings lead to increased catecholamine release by stimulating central and peripheral chemoreceptors and eliminating the reflex inhibition of sympathetic activity. [11] Hypoxaemia and retention of CO2 in sleep apnoea cause chemoreflex-mediated increases in sympathetic activity with consequent vasoconstriction and acceleration of the heart rate.[12] This can lead to marked fluctuations in blood pressure.[13
15]

Changes in oxygenation and intrathoracic pressure have also been associated with acute changes in pulmonary vascular resistance. Pulmonary artery pressure increases over the course of an apnoeic episode due to a combination of progressive hypoxia, decreased intrathoracic pressure, increased right heart output, and decreased left heart compliance[16] (Figure 2).

Figure 2.

Effects of obstructive sleep apnoea on pulmonary and nervous systems. These derangements lead to systemic organ damage via inflammatory mediators.

Furthermore, hypoxia activates nucleated cells in the body, which sense and respond to reduced oxygen tension.[17] The condition stimulates transcription factors such as hypoxia-inducible factor 1 (HIF-1) and nuclear factor B (NF-B) which regulate the expression of genes that mediate inflammatory responses.[8,17] This process generates reactive oxygen species that consume intravascular nitric oxide (NO), and impair endothelial-mediated vasodilation.[18] Nuclear factor B orchestrates the expression of cytokines [tumour necrosis factor (TNF)-alpha, IL-6, and IL-8], adhesion molecules (VCAM-1, E- and L-selectin, ICAM-1, and CD15), and cyclo-oxygenase enzymes (cyclo-oxygenase 1).[19,20] Hypoxia-inducible factor 1 promotes angiogenesis and can potentiate atherosclerosis by stimulating vascularization within the atherosclerotic plaque.[2124] Inflammatory cytokines enhance the survival of myeloid inflammatory cells, such as granulocytes, monocytes, and macrophages, increasing their functional longevity and inflammation. [17] Sleep apnoea is independently associated with higher levels of C-reactive protein, IL-6, IL-8, IL-18, TNF-alpha, homocystine, leptin, and matrix metalloproteinase-9.[2530] The severity of sleep apnoea, and, particularly, the severity of oxyhaemoglobin desaturation, is linked to increased levels of TNF-alpha and IL-6, cytokines which relate to hyperglycaemia, increased basal beta-cell function, insulin resistance, and overt type 2 diabetes.[3135] In patients with type 2 diabetes, OSA is associated with poorer glucose control measured by HgB A1C, independent of adiposity and other confounders.[36] Cross-sectional studies have shown a correlation between hyperlipidaemia and sleep apnoea, with obesity as a possible confounder.[37,38] Animal models have demonstrated a direct link between hypoxia and elevated cholesterol and liver triglyceride content.[39] Sleep apnoea may even play a role in the development of nonalcoholic steatohepatitis (NASH), with one study finding the prevalence of sleep apnoea to be near 50% in patients with NASH.[40,41] Inflammation provoked by chronic sleep apnoea might cause considerable endothelial damage. Sleep apnoea patients have increased numbers of circulating apoptotic endothelial cells compared with controls. These levels correlate with abnormal brachial artery flow-mediated dilation, a marker of endothelial dysfunction.[42] Increased intima-media thickness, associated with higher levels of C-reactive protein, IL-6, and IL-18, is also strongly related to the duration of nocturnal oxyhaemoglobin desaturation.[43,44] This vascular compromise is a common pathway for the development of multi-organ dysfunction (Figure 3).

Figure 3.

Postulated mechanisms underlying the relationship between sleep apnoea and cardiac disease. Note the many mechanisms (third level) by which hypoxaemia may lead to cardiovascular abnormalities.

Hypertension
Large cross-sectional and longitudinal studies have shown a strong correlation between chronic sleep apnoea and arterial hypertension, independent of potential confounders.[4547] A large prospective study also demonstrated a strong association between the presence of sleep apnoea and the development of hypertension.[48] A distinct feature of sleep apnoea-induced hypertension is loss of the normal nocturnal decrease in blood pressure. This indicates a link between these two disorders.[49] Intermittent hypoxia and reoxygenation, as well as the stress of haemodynamic derangements and frequent awakenings, lead to decreased NO levels, higher catecholamine levels, and increased blood pressure. These

changes are partially reversible with continuous positive airway pressure (CPAP) therapy as demonstrated by numerous well designed randomized, controlled studies.[5053] Treatment is especially important in cases of resistant hypertension since more than 80% of these patients have been reported to have sleep apnoea.[47] The relationship between sleep apnoea and hypertension may be even more complex. Resistant hypertension is highly correlated with hyperaldosteronism, which promotes accumulation of fluid within the neck and can worsen sleep apnoea. Moreover, increasing evidence suggests that blocking aldosterone in patients with resistant hypertension can both improve the severity of sleep apnoea while decreasing blood pressure.[5456]

Coronary Artery Disease and Acute Coronary Syndrome

The correlation between sleep apnoea and the development of CAD and acute coronary syndrome (ACS) has been well established.[5759] In one study, sleep apnoea was found in 65.7% of patients admitted to the hospital for acute myocardial infarction (MI).[60] The co-existence of CAD and sleep apnoea portends a poor prognosis with a large prospective study demonstrating a 70% relative and a 10.7% absolute increase in death, cerebrovascular events, and MIs compared with those having CAD alone.[61] A similar study demonstrated that in patients treated successfully with percutaneous coronary intervention after an ACS, the presence of sleep apnoea was associated with higher mortality (38 vs. 9%), increased rate of stent restenosis (24 vs. 5%), and increased rate of major adverse cardiac events (37 vs. 15%) within 1 year.[62] Optimal treatment of sleep apnoea may have important clinical implications for patients with refractory angina. A small study done on patients who suffered from nocturnal angina showed that 9 out of 10 patients were suffering from sleep apnoea, with a consistent temporal association between apnoeic episodes and the onset of angina. The administration of CPAP diminished the number of anginal episodes and the number of nocturnal myocardial ischaemic events.[63] There are also case reports of patients suffering from typical angina symptoms, without critical CAD seen on cardiac catheterization, who were found to be suffering from sleep apnoea. [64] Although treatment of sleep apnoea has not been shown to reverse progression of CAD, it might retard its progression. Treatment of sleep apnoea with CPAP can decrease the rate of occurrence of new cardiovascular events in patients with known CAD.[65] The results from the large 'Randomized Intervention with CPAP in Coronary Artery Disease and Sleep Apnoea' (RICCADSA trial) are still pending but will soon help to shed light on the benefit of CPAP in this population.[66] Sleep apnoea increases blood coagulability and viscosity,[67] These patients have increased platelet aggregability, higher levels of clotting factors, and reduced fibrinolytic capacity.[68] These findings could, in addition to contributing to CAD progression, predispose to thrombus formation and in-stent thrombosis.

Arrhythmia
Sleep apnoea is associated with hypoxia, autonomic derangements, and cardiac structural changes, all of which predispose to arrhythmia. Cross-sectional studies have indicated a strong association between atrial fibrillation (AF) and sleep apnoea, independent of age, sex, hypertension, HF, and body mass index.[69] These studies have reported a sleep apnoea prevalence of 4373% among those with AF, with high rates of CAD and CSA in this group.[70] The degree of nocturnal hypoxia was also shown to be directly correlated with the risk of developing AF.[71,72] Hypoxia causes autonomic abnormalities, diastolic dysfunction, and systemic inflammation leading to cardiac remodelling and alterations in cardiac conduction leading to the development of AF.[72,73] The presence of OSA portends a 25% greater risk of AF recurrence after catheter ablation.[74] Treatment with CPAP prior to an ablation procedure is associated with an eight-fold improvement in the lasting success of this procedure.[75,76] Sleep apnoea, especially in association with HF, has been linked to a host of other cardiac dysrhythmias, including nocturnal paroxysmal asystole, bradyarrythmias, atrioventricular nodal block, supraventricular tachycardia, and non-sustained ventricular tachycardia.[77] People with OSA have dramatically increased risk of sudden cardiac death during sleep. This risk was clearly associated with the AHI. [78] A study of HF sufferers with implanted defibrillators further demonstrated that sleep disordered breathing is associated with an increased incidence of malignant ventricular arrhythmias.[79] A similar study demonstrated a predominance of nocturnal

life-threatening ventricular arrhythmias in sleep apnoea patients with no significant increase in daytime arrhythmic activity.[80] Treatment with CPAP decreases nocturnal rates of sinus bradycardia, sinus pauses, paroxysmal AF, premature ventricular contractions, and ventricular ectopy.[8183] In one study, CPAP completely eliminated pathologically significant nocturnal rhythm disturbances in seven of eight patients.[84]

Heart Failure
Sleep apnoea is extremely common in people with heart failure. Estimates of prevalence are as high as 47 76%.[8588] Alarmingly, one study reported an average AHI of 44 in HF patients with sleep apnoea. [88] The relationship between sleep apnoea and HF is complex. Chronic sleep apnoea causes a series of derangements that could potentially lead to the development or exacerbation of HF. Hypoxaemia, often aggravated by coexisting anaemia, is linked with acute increases in BNP concentrations in patients with HF, independent of the frequency of apnoeic events.[89] Furthermore, hypertension, CAD, diabetesall well established risk factors for HFare adversely impacted by sleep apnoea. Sleep apnoea induced increase in sympathetic tone and heart rate are especially detrimental in HF. The heightened level of stimulation is maladaptive to an already failing heart and can lead to myocyte injury, cardiac beta-adrenoreceptor desensitization, and functional and structural abnormalities.[90] Studies have also shown that higher sympathetic activity is associated with worse outcomes in HF.[91,92] Updated HF guidelines are beginning to stress the importance of carefully screening and treating HF patients for sleep apnoea. [93] Heart failure can both cause and exacerbate OSA and CSA, initiating a potentially devastating cycle. The severity of HF, as measured by cardiac index, correlates with the degree of CSA.[4,95] Fluid shifts while supine result in increased neck vein congestion, neck circumference, pharyngeal airflow resistance, and pharyngeal collapsibility, all of which cause obstructive symptoms.[96] HF is also linked with Cheyne-Stokes respiration; animal models suggest that pulmonary congestion activates lung vagal irritant receptors, which causes hyperventilation and decreased CO2, as well as stretch receptors, which elicits a strong inhibitory reflex (HeringBreuer inflation reflex). This reflex results in a cessation of breathing followed by a period of arousal and hyperventilation that further destabilizes breathing.[97,98] In addition, prolonged circulation time may play a role, with the increase in circulatory delay in HF patients altering physiological feedback mechanisms [99] (Figure 1). Cheyne-Stokes respirations are a powerful independent predictor of poor prognosis in patients with CHF.[100] Patients with severe heart failure can even experience Cheyne-Stokes respirations during daytime. This phenomenon is associated with higher levels of biomarkers of cardiac dysfunction and is an independent predictor of mortality.[101,102] It is important to note that the classic symptoms of Cheyne-Stokes respiration, which are fragmented sleep, paroxysmal nocturnal dyspnoea, orthopnoea, and daytime fatigue, can easily be interpreted as worsening HF symptoms.[103] Treatment of CSA may improve HF symptoms and quality of life. Diastolic dysfunction is also highly correlated with sleep disordered breathing and nocturnal hypoxaemia. [104107] The prevalence of sleep apnoea in patients who have HF with preserved ejection has been reported to be as high as 70%, with a predominance of OSA.[108] The cause of the link between OSA and diastolic dysfunction is not well defined, and could be related to hypertension, obesity, ischaemic heart disease, or other factors.

Pulmonary Hypertension
Classically, sleep apnoea has been associated with pulmonary hypertension (PH) and cor pulmonale. Indeed, after excluding people with primary lung diseases, the prevalence of PH is ~1520% in sleep apnoea patients.[109] The development of PH is not, however, related to the severity of sleep apnoea symptoms,[109,110] and it is uncertain how often the sleep apnoea or the concomitant abnormalities are the cause. For example, nearly half of sleep apnoea patients with PH have increased pulmonary capillary wedge pressure, suggesting left heart dysfunction.[111] In other patients, the presence of PH appears to be related to the amount of sleep time with oxygen saturation <90%.[112,113] Continuous positive airway pressure shows some benefit in reversing pulmonary arterial hypertension. In the only controlled trial of CPAP which specifically looked at pulmonary artery pressures, effective CPAP reduced average pulmonary systolic pressure by 5 mmHg. [114]

Diagnosis

The wide range of possible severe consequences of untreated sleep apnoea mandates prompt diagnosis. The gold standard is monitored polysomnography in a sleep laboratory. This modality uses multiple biometric recording devices to accurately quantify the number of apnoea (a 90% reduction in tidal volume lasting >10s) and hypopnoea (a reduction in tidal volume of 5090%, lasting >10s accompanied by >3% decrease in oxyhaemoglobin saturation) episodes occurring during a night's sleep. Despite the high sensitivity and specificity of polysomnography referral for a sleep study is often difficult, inconvenient, and expensive. For this reason, a number of ambulatory screening systems have been devised. Some devices can record information on multiple data sets including respiratory pattern, respiratory effort, pulse oximetry, heart rate, and peripheral arterial tone. Other devices record only one signal. In general, the more complex devices can obtain very high positive predictive values at the expense of negative predictive values,[15] whereas more basic devices, such as nocturnal oximetry, are highly effective at ruling out sleep apnoea (negative predictive value 96.9%)[116] but suffer in terms of their ability to reliably confirm the diagnosis. Recent studies show that for selected patients with a high pre-test probability of having sleep apnoea, homebased diagnostic and monitoring systems are not inferior to conventional hospital-based polysomnographic diagnosis, with significantly lower cost.[117,118] Moreover, a home-based approach to diagnosis and treatment may facilitate remote monitoring and may promote greater compliance. The Portable Monitoring Task Force of the American Academy of Sleep Medicine recommends that unattended portable monitoring for the diagnosis of OSA should be performed in conjunction with a comprehensive sleep evaluation. They also recommend that portable monitoring should be used as an alternative to polysomnography only in patients with high pre-test probability of moderate to severe OSA.[119]

Management
Once sleep apnoea has been diagnosed, the first remedial steps involve eliminating aggravating factors. This includes avoidance of alcohol or sedating medications, elevation of the head of the bed, and change of sleeping position to one's side to prevent the tongue from falling back and obstructing the airway. Patients should also be encouraged to lose weight. A 10% weight reduction correlated with a 26% decrease in AHI in a population-based study.[120] HF treatment should be optimized with an emphasis on minimizing extravascular fluid accumulation with effective diuresis.[121] Angiotensin-converting enzyme inhibitors and beta-blockers have both been shown to reduce CSA in CHF, presumably by improving the underlying HF.[122,123] The standard treatment for patients diagnosed with OSA is nocturnal CPAP usually delivered via a tight fitting nasal mask. Continuous positive airway pressure should be offered to all patients diagnosed with OSA, as the benefits of CPAP in this population are unquestionable. Continuous positive airway pressure therapy has been shown to lower blood pressure,[124]reduce cardiac rhythm disturbances,[84] decrease cholesterol,[40] improve insulin resistance and management of diabetes,[125,126] reduce the levels of inflammatory cytokines, reverse autonomic derangement,[28,49] and improve endothelial function.[127] Several long-term studies have also reported that CPAP reduces the incidence of cardiovascular disease and improves long-term cardiovascular morbidity and mortality among patients with severe sleep apnoea.[61,128] Heart failure patients require special consideration due to the high incidence of both OSA and CSA. In those with a predominance of OSA, CPAP once again has shown some benefit, although evidence of long-term improvements in morbidity and mortality from randomized controlled trials is lacking. Studies have shown that CPAP decreases sympathetic activation, improves systolic function, significantly reduces the left ventricular end-systolic diameter, and improves quality of life.[129131] In one study, CPAP improved the left ventricular ejection fraction from an average of 25 to 33.8%.[130] The treatment of CSA in HF is controversial. Since CSA is likely a manifestation of advanced HF, optimizing medical management of HF may improve symptoms of CSA. The largest randomized study, 'Canadian Continuous Positive Airway Pressure for Patients With CSA and HF' (CANPAP), demonstrated no effect on heart transplant-free survival, but this trial was underpowered. It did, however, demonstrate improvements in apnoea frequency, blood oxygenation, norepinephrine levels, and LV function.[132] Other assisted breathing devices have shown promising results. Flow-targeted dynamic bilevel positive airway pressure (BPAP), which modulates inspiratory pressure in order to maintain a target inspiratory airflow has been shown to be especially effective in CSA. That is likely due to the associated pulmonary oedema and reduced lung compliance which can be impacted by BPAP.[133] Adaptive servo-ventilation (ASV) therapy is a

new positive airway pressure technology that tracks a patient's breathing pattern and adjusts breath-by-breath pressure support to counterbalance the fluctuations in respiratory rate. It will decrease the rate of pressure supported ventilation during periods of hyperventilation and increase the rate during apnoeas. In non-blinded studies, ASV improved markers of cardiac function (LVEF, NYHA class, NT-pro BNP, C-reactive protein) as well as quality of life, exercise capacity, and respiratory stability in HF patients with Cheyne-Stokes respiration, comparing favourably to CPAP.[134139] A study of ASV in people with complex sleep apnoea (HF patients who developed CSA while being treated with CPAP for OSA) showed similar benefits in terms of cardiac function and respiratory stability.[140] Although long-term outcome data for ASV are currently lacking, trials are underway. Since the use of nocturnal supplemental oxygen significantly reduces apnoea-related hypoxia in CSA,[141,142] theoretically this might lead to long-term benefit. Studies to date have shown some benefit in terms of ameliorating nocturnal desaturations and periodic breathing, but no benefit in terms of cardiac function, morbidity, or mortality.[143,144] Current guidelines do not recommend the use of oxygen therapy in sleep apnoea, as supplemental oxygen alone may prolong apnoeas and may potentially worsen nocturnal hypercapnia in patients with co-morbid respiratory disease.[99] For patients unable to tolerate CPAP therapy, less effective options have shown some benefit, including behavioural treatments, dental appliances that prevent the jaw from sliding backwards, and surgery of the soft palate and nasoskeleton to open the posterior airway passage.[99] Voice exercises, neck muscle strengthening manoeuvers, and even playing the didgeridoo (an indigenous Australian wind instrument) have been shown to improve the symptoms of moderate sleep apnoea.[145] An exciting new modality in the pipeline is transvenous phrenic nerve electrostimulation to stimulate diaphragmatic motion in CSA.[146] While clinical trials are still ongoing, preliminary data appear promising ().
Table 1. Clinical presentation of HBV-related membranous nephropathy. Effect Intervention Obstructive sleep apnoea Central sleep apnoea

Weight loss Optimization of heart failure

Improvement in sleep apnoea symptoms and AHI No clear benefit

No proven benefit Improvement in central sleep apnoea and decrease in heart failure-related morbidity and mortality

CPAP

No proven decrease in morbidity and mortality; Proven benefit in terms of AHI as likely improvements in apnoea frequency, blood well as cardiovascular morbidity and oxygenation, norepinephrine levels, and LV mortality function Comparable efficacy to CPAP Questionably more beneficial than CPAP in reducing symptoms and AHI; no data on relative improvements in morbidity and mortality Favourably compares to CPAP in terms of markers of cardiac function as well as symptom reduction; no definitive data on improvement in morbidity and mortality Some benefit reported in nocturnal desaturation and periodic breathing, but no proven benefit in cardiac function, morbidity, or mortality (currently not recommended)

BiPap

ASV

No clear advantage over CPAP

Nocturnal oxygen supplementation

Less effective than CPAP in reduction of symptoms or AHI (currently not recommended)

Behavioural modifications, muscle training, surgery Phrenic nerve stimulation

Some benefit in decreasing AHI and symptoms, no proven improvement No proven or theoretical benefit in cardiovascular morbidity or mortality No proven or theoretical benefit Immediate decrease in apnoea frequency and nocturnal desaturations: long-term data lacking

Conclusion
Sleep apnoea is a common chronic disorder with potentially devastating consequences. It induces numerous physical and biochemical derangements. Sleep apnoea is pro-inflammatory, with nocturnal oxygen desaturations and hypercapnia appearing to play a pivotal role in this process. It is independently associated with an increased risk of death of any cause.[147] Sleep apnoea even poses a societal risk since sufferers are prone to sleep-deprived driving accidents. Diagnosis and management of sleep apnoea can be difficult. Symptoms of sleep apnoea are not easily indentified, and as many as 80% of sufferers remain undiagnosed.[148] This diagnostic gap should begin to close as awareness rises of the high prevalence of sleep apnoea in many common diseases. High-risk patients for sleep apnoea include the obese, those with treatment refractory hypertension, type 2 diabetes, CAD, stroke, MIs, congestive HF, AF, nocturnal dysrhythmias, and PH. Even the gold standards of diagnosis and treatment suffer from major drawbacks. Polysomnography is expensive and inconvenient, and successful CPAP treatment is often hindered by frequent intolerance and widespread non-compliance. Sleep apnoea is one of the most prevalent and dangerous cardiac risk factors, and future research will hopefully shed more light on the effects of this disease, as well as provide more effective options for management and treatment.
References

1. 2. 3. 4. 5. 6. 7. 8. 9.

Hauri PJ, ed. The International Classification of Sleep Disorders, Diagnostic and Coding Manual . 2nd ed. Westchester, IL: American Academy of Sleep Medicine, 2005. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:12301235. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:12171239. Malhotra A, White DP. Obstructive sleep apnoea. Lancet 2002;360:237245. Lanfranchi PA, Somers VK, Braghiroli A, Corra U, Eleuteri E, Giannuzzi P. Central sleep apnea in left ventricular dysfunction: prevalence and implications for arrhythmic risk. Circulation 2003;107:727732. Narkiewicz K, van de Borne PJ, Pesek CA, Dyken ME, Montano N, Somers VK. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation 1999;99:11831189. Javaheri S. A mechanism of central sleep apnea in patients with heart failure. N Engl J Med 1999;341:949954. Bonsignore MR, Marrone O, Insalaco G, Bonsignore G. The cardiovascular effects of obstructive sleep apnoeas: analysis of pathogenic mechanisms. Eur Respir J 1994;7:786805. Virolainen J, Ventil M, Turto H, Kupari M. Effect of negative intrathoracic pressure on left ventricular pressure dynamics and relaxation. J Appl Physiol 1995;79:455460.

10. Scharf SM, Graver LM, Balaban K. Cardiovascular effects of periodic occlusions of the upper airways in dogs. Am Rev Respir Dis 1992;146:321329. 11. Somers VK, Mark AL, Zavala DC, Abboud FM. Influence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal humans. J Appl Physiol 1989;67:20952100. 12. Somers VK, Mark AL, Zavala DC, Abboud FM. Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans. J Appl Physiol 1989;67:21012106. 13. Brooks D, Horner RL, Kozar LF, Render-Teixeira CL, Phillipson EA. Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model. J Clin Invest 1997;99:106109. 14. Lesske J, Fletcher EC, Bao G, Unger T. Hypertension caused by chronic intermittent hypoxia influence of chemoreceptors and sympathetic nervous system. J Hypertens 1997;15:15931603.

15. Loredo JS, Ziegler MG, Ancoli-Israel S, Clausen JL, Dimsdale JE. Relationship of arousals from sleep to sympathetic nervous system activity and BP in obstructive sleep apnea. Chest 1999;116:655659. 16. Golbin JM, Somers VK, Caples SM. Obstructive sleep apnea, cardiovascular disease, and pulmonary hypertension. Proc Am Thorac Soc 2008;5:200206. 17. Garvey JF, Taylor CT, McNicholas WT. Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. Eur Respir J 2009;33:11951205. 18. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011;364:656665. 19. Ryan S, McNicholas WT, Taylor CT. A critical role for p38 map kinase in NF-kB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun 2007;355:728733. 20. Htoo AK, Greenberg H, Tongia S, Chen G, Henderson T, Wilson D, Liu SF. Activation of nuclear factor kappaB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath 2006;10:4350. 21. Yuan G, Khan SA, Luo W, Nanduri J, Semenza GL, Prabhakar NR. Hypoxia-inducible factor 1 mediates increased expression of NADPH oxidase-2 in response to intermittent hypoxia. J Cell Physiol 2011;226:29252933. 22. Semenza GL, Prabhakar N. HIF-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia. Antioxid Redox Signal 2007;9:13911396. 23. Cramer T, Yamanishi Y, Clausen BE, Frster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS. HIF-1alpha is essential for myeloid cellmediated inflammation. Cell 2003;112:645657. 24. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol 2009;218:729. 25. Lui MM, Lam JC, Mak HK, Xu A, Ooi C, Lam DC, Mak JC, Khong PL, Ip MS. C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity. Chest 2009;135:950956. 26. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Hirano T, Adachi M. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003;107:11291134. 27. Kokturk O, Ciftci TU, Mollarecep E, Ciftci B. Elevated C-reactive protein levels and increased cardiovascular risk in patients with obstructive sleep apnea syndrome. Int Heart J 2005;46:801809. 28. Kokturk O, Ciftci TU, Mollarecep E, Ciftci B. Serum homocysteine levels and cardiovascular morbidity in obstructive sleep apnea syndrome. Respir Med 2006;100:536541. 29. Ye J, Liu H, Li Y, Liu X, Zhu JM. Increased serum levels of C-reactive protein and matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Chin Med J (Engl) 2007;120:14821486. 30. Ciftci TU, Kokturk O, Bukan N, Bilgihan A. The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine 2004;28:8791. 31. Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002;165:670676. 32. Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 2002;165:677 682. 33. Pallayova M, Steele KE, Magnuson TH, Schweitzer MA, Hill NR, Bevans-Fonti S, Schwartz AR. Sleep apnea predicts distinct alterations in glucose homeostasis and biomarkers in obese adults with normal and impaired glucose metabolism. Cardiovasc Diabetol 2010;9:83.

34. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 1997;82:4167 4170. 35. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000;11:212217. 36. Aronsohn RS, Whitmore H, Van Cauter E, Tasali E. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med 2010;181:507513. 37. Newman AB, Nieto FJ, Guidry U, Lind BK, Redline S, Pickering TG, Quan SF. Relation of sleepdisordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol 2001;154:5059. 38. Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR. Circulating cardiovascular risk factors in obstructive sleep apnea: data from randomized controlled trials. Thorax 2004;59:777782. 39. Li J, Thorne LN, Punjabi NM, Sun CK, Schwartz AR, Smith PL, Marino RL, Rodriguez A, Hubbard WC, O'Donnell CP, Polotsky VY. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 2005;97:698706. 40. Singh H, Pollock R, Uhanova J, Kryger M, Hawkins K, Minuk GY. Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2005;50:23382343. 41. Tann F, Gagnadoux F, Chazouillres O, Fleury B, Wendum D, Lasnier E, Lebeau B, Poupon R, Serfaty L. Chronic liver injury during obstructive sleep apnea. Hepatology 2005;41:12901296. 42. El Solh AA, Akinnusi ME, Baddoura FH, Mankowski CR. Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction. Am J Respir Crit Care Med 2007;175:11861191. 43. Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi-Filho G. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2005;172:613618. 44. Minoguchi K, Yokoe T, Tazaki T, Minoguchi H, Tanaka A, Oda N, Okada S, Ohta S, Naito H, Adachi M. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005;172:625630. 45. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:18291836. 46. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. Br Med J 2000;320:479482. 47. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, Leung RS, Bradley TD. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001;19:2271 2277. 48. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleepdisordered breathing and hypertension. N Engl J Med 2000;342:13781384. 49. Loredo JS, Ancoli-Israel S, Dimsdale JE. Sleep quality and blood pressure dipping in obstructive sleep apnea. Am J Hypertens 2001;14(9 Pt 1):887892. 50. Becker HF, Jerrentrup A, Ploch T, Grote L, Penzel T, Sullivan CE, Peter JH. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003;107:6873. 51. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, Davies RJ. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002;359:204210.

52. Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med 2001;163:344348. 53. Suzuki M, Otsuka K, Guilleminault C. Long-term nasal continuous positive airway pressure administration can normalize hypertension in obstructive sleep apnea patients. Sleep 1993;16:545 549. 54. Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens 2011; http://dx.doi.org/10.1038/jhh.2011.47 [Epub ahead of print] 55. Thomopoulos C, Michalopoulou H, Kasiakogias A, Kefala A, Makris T. Resistant hypertension and obstructive sleep apnea: the sparring partners. Int J Hypertens 2011;2011:947246. 56. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007;131:453459. 57. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, O'Connor GT, Boland LL, Schwartz JE, Samet JM. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001;163:1925. 58. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:10461053. 59. Savransky V, Nanayakkara A, Li J, Bevans S, Smith PL, Rodriguez A, Polotsky VY. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med 2007;175:12901297. 60. Lee CH, Khoo SM, Tai BC, Chong EY, Lau C, Than Y, Shi DX, Lee LC, Kailasam A, Low AF, Teo SG, Tan HC. Obstructive sleep apnea in patients admitted for acute myocardial infarction. Prevalence, predictors, and effect on microvascular perfusion. Chest 2009;135:14881495. 61. Mooe T, Franklin KA, Holmstrm K, Rabben T, Wiklund U. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med 2001;164:19101913. 62. Yumino D, Tsurumi Y, Takagi A, Suzuki K, Kasanuki H. Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. Am J Cardiol 2007;99:2630. 63. Franklin KA, Nilsson JB, Sahlin C, Naslund U. Sleep apnoea and nocturnal angina. Lancet 1995;345:10851087. 64. Loui WS, Blackshear JL, Fredrickson PA, Kaplan J. Obstructive sleep apnea manifesting as suspected angina: report of three cases. Mayo Clin Proc 1994;69:244248. 65. Milleron O, Pillire R, Foucher A, de Roquefeuil F, Aegerter P, Jondeau G, Raffestin BG, Dubourg O. Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study. Eur Heart J 2004;25:728734. 66. Peker Y, Glantz H, Thunstrm E, Kallryd A, Herlitz J, Ejdebck J. Rationale and design of the randomized intervention with cpap in coronary artery disease and sleep apnoeaRICCADSA trial. Scand Cardiovasc J 2009;43:2431. 67. Nobili L, Schiavi G, Bozano E, De Carli F, Ferrillo F, Nobili F. Morning increase of whole blood viscosity in obstructive sleep apnea syndrome. Clin Hemorheol Microcirc 2000;22:2127. 68. Sanner BM, Konermann M, Tepel M, Groetz J, Mummenhoff C, Zidek W. Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J 2000;16:648652. 69. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, Somers VK. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007;49:565571.

70. Altmann DR, Ullmer E, Rickli H, Maeder MT, Sticherling C, Schaer BA, Osswald S, Ammann P. Clinical impact of screening for sleep related breathing disorders in atrial fibrillation. Int J Cardiol 2012;154:256258. 71. Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung TK, Nattel S. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 2003;107:19301936. 72. Mehra R, Benjamin EJ, Shahar E, Gottlieb DJ, Nawabit R, Kirchner HL, Sahadevan J, Redline S; Sleep Heart Health Study. Association of nocturnal arrhythmias with sleep-disordered breathing: the Sleep Heart Health Study. Am J Respir Crit Care Med 2006;173:910916. 73. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:28862891. 74. Ng CY, Liu T, Shehata M, Stevens S, Chugh SS, Wang X. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol 2011;108:4751. 75. Patel D, Mohanty P, Di Biase L, Shaheen M, Lewis WR, Quan K, Cummings JE, Wang P, Al-Ahmad A, Venkatraman P, Nashawati E, Lakkireddy D, Schweikert R, Horton R, Sanchez J, Gallinghouse J, Hao S, Beheiry S, Cardinal DS, Zagrodzky J, Canby R, Bailey S, Burkhardt JD, Natale A. Safety and efficacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: the impact of continuous positive airway pressure. Circ Arrhythm Electrophysiol 2010;3:445451. 76. Bitter T, Nlker G, Vogt J, Prinz C, Horstkotte D, Oldenburg O. Predictors of recurrence in patients undergoing cryoballoon ablation for treatment of atrial fibrillation: the independent role of sleepdisordered breathing. J Cardiovasc Electrophysiol 2012;23:1825. 77. Roche F, Xuong AN, Court-Fortune I, Costes F, Pichot V, Duverney D, Vergnon JM, Gaspoz JM, Barthlmy JC. Relationship among the severity of sleep apnea syndrome, cardiac arrhythmias, and autonomic imbalance. Pacing Clin Electrophysiol 2003;26:669677. 78. Gami AS, Howard DE, Olson EJ, Somers VK. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med 2005;352:12061214. 79. Bitter T, Westerheide N, Prinz C, Hossain MS, Vogt J, Langer C, Horstkotte D, Oldenburg O. CheyneStokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Heart J 2011;32:6174. 80. Zeidan-Shwiri T, Aronson D, Atalla K, Blich M, Suleiman M, Marai I, Gepstein L, Lavie L, Lavie P, Boulos M. Circadian pattern of life-threatening ventricular arrhythmia in patients with sleep-disordered breathing and implantable cardioverter-defibrillators. Heart Rhythm 2011;8:657662. 81. Javaheri S. Effects of continuous positive airway pressure on sleep apnea and ventricular irritability in patients with heart failure. Circulation 2000;101:392397. 82. Ryan CM, Usui K, Floras JS, Bradley TD. Effect of continuous positive airway pressure on ventricular ectopy in heart failure patients with obstructive sleep apnoea. Thorax 2005;60:7815. 83. Abe H, Takahashi M, Yaegashi H, Eda S, Tsunemoto H, Kamikozawa M, Koyama J, Yamazaki K, Ikeda U. Efficacy of continuous positive airway pressure on arrhythmias in obstructive sleep apnea patients. Heart Vessels 2010;25:6369. 84. Harbison J, O'Reilly P, McNicholas WT. Cardiac rhythm disturbances in the obstructive sleep apnea syndrome: effects of nasal continuous positive airway pressure therapy. Chest 2000;118:591595. 85. Sin DD, Fitzgerald F, Parker JD, Newton G, Floras JS, Bradley TD. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 1999;160:11011106.

86. Vazir A, Hastings PC, Dayer M, McIntyre HF, Henein MY, Poole-Wilson PA, Cowie MR, Morrell MJ, Simonds AK. A high prevalence of sleep disordered breathing in men with mild symptomatic chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 2007;9:243250. 87. Javaheri S. Sleep disorders in systolic heart failure: a prospective study of 100 male patients. The final report. Int J Cardiol 2006;106:2128. 88. Javaheri S, Parker TJ, Liming JD, Corbett WS, Nishiyama H, Wexler L, Roselle GA. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences and presentations. Circulation 1998;97:21542159. 89. Gottlieb JD, Schwartz AR, Marshall J, Ouyang P, Kern L, Shetty V, Trois M, Punjabi NM, Brown C, Najjar SS, Gottlieb SS. Hypoxia, not the frequency of sleep apnea, induces acute hemodynamic stress in patients with chronic heart failure. J Am Coll Cardiol 2009;54:17061712. 90. Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 1993;22:72A-84A. 91. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:12571263. 92. Cohn JN. Abnormalities of peripheral sympathetic nervous system control in congestive heart failure. Circulation 1990;82(2 Suppl):I59I67. 93. McKelvie RS, Moe GW, Cheung A, Costigan J, Ducharme A, Estrella-Holder E, Ezekowitz JA, Floras J, Giannetti N, Grzeslo A, Harkness K, Heckman GA, Howlett JG, Kouz S, Leblanc K, Mann E, O'Meara E, Rajda M, Rao V, Simon J, Swiggum E, Zieroth S, Arnold JM, Ashton T, D'Astous M, Dorian P, Haddad H, Isaac DL, Leblanc MH, Liu P, Sussex B, Ross HJ. The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol 2011;27:319338. 94. Solin P, Bergin P, Richardson M, Kaye DM, Walters EH, Naughton MT. Influence of pulmonary capillary wedge pressure on central apnea in heart failure. Circulation 1999;99:15741579. 95. Oldenburg O, Bitter T, Wiemer M, Langer C, Horstkotte D, Piper C. Pulmonary capillary wedge pressure and pulmonary arterial pressure in heart failure patients with sleep-disordered breathing. Sleep Med 2009;10:726730. 96. Yumino D, Redolfi S, Ruttanaumpawan P, Su MC, Smith S, Newton GE, Mak S, Bradley TD. Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation 2010;121:15981605. 97. Bradley TD, Floras JS. Sleep apnea and heart failure: Part II: central sleep apnea. Circulation 2003;107:1822. 98. Paintal AS. Vagal sensory receptors and their reflex effects. Physiol Rev 1973;53:159227. 99. Epstein LJ, Kristo D, Strollo PJ Jr., Friedman N, Malhotra A, Patil SP, Ramar K, Rogers R, Schwab RJ, Weaver EM, Weinstein MD; Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009;5:263. 100. Lanfranchi PA, Braghiroli A, Bosimini E, Mazzuero G, Colombo R, Donner CF, Giannuzzi P. Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation 1999;99:14351440. 101. La Rovere MT, Pinna GD, Maestri R, Robbi E, Mortara A, Fanfulla F, Febo O, Sleight P. Clinical relevance of short-term day-time breathing disorders in chronic heart failure patients. Eur J Heart Fail 2007;9:949954.

102. Poletti R, Passino C, Giannoni A, Zyw L, Prontera C, Bramanti F, Clerico A, Piepoli M, Emdin M. Risk factors and prognostic value of daytime Cheyne-Stokes respiration in chronic heart failure patients. Int J Cardiol 2009;137:4753. 103. Naughton M, Benard D, Tam A, Rutherford R, Bradley TD. Role of hyperventilation in the pathogenesis of central sleep apneas in patients with congestive heart failure. Am Rev Respir Dis 1993;148:330338. 104. Kraiczi H, Caidahl K, Samuelsson A, Peker Y, Hedner J. Impairment of vascular endothelial function and left ventricular filling: association with the severity of apnea-induced hypoxemia during sleep. Chest 2001;119:10851091. 105. Fung JW, Li TS, Choy DK, Yip GW, Ko FW, Sanderson JE, Hui DS. Severe obstructive sleep apnea is associated with left ventricular diastolic dysfunction. Chest 2002;121:422429. 106. Usui Y, Takata Y, Inoue Y, Tomiyama H, Kurohane S, Hashimura Y, Kato K, Saruhara H, Asano K, Shiina K, Yamashina A. Severe obstructive sleep apnea impairs left ventricular diastolic function in non-obese men. Sleep Med 2011. 107. Baguet JP, Barone-Rochette G, Lvy P, Vautrin E, Pierre H, Ormezzano O, Ppin JL. Left ventricular diastolic dysfunction is linked to severity of obstructive sleep apnoea. Eur Respir J 2010;36:13231329. 108. Bitter T, Faber L, Hering D, Langer C, Horstkotte D, Oldenburg O. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail 2009;11:602608. 109. Kessler R, Chaouat A, Weitzenblum E, Oswald M, Ehrhart M, Apprill M, Krieger J. Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences. Eur Respir J 1996;9:787794. 110. Bady E, Achkar A, Pascal S, Orvoen-Frija E, Laaban JP. Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax 2000;55:934939. 111. Weitzenblum E, Krieger J, Apprill M, Valle E, Ehrhart M, Ratomaharo J, Oswald M, Kurtz D. Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am Rev Respir Dis 1988;138:345349. 112. Krieger J, Sforza E, Apprill M, Lampert E, Weitzenblum E, Ratomaharo J. Pulmonary hypertension, hypoxemia, and hypercapnia in obstructive sleep apnea patients. Chest 1989;96:729 737. 113. Sajkov D, Cowie RJ, Thornton AT, Espinoza HA, McEvoy RD. Pulmonary hypertension and hypoxemia in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1994;149:416422. 114. Arias MA, Garca-Ro F, Alonso-Fernndez A, Martnez I, Villamor J. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J 2006;27:11061113. 115. Flemons WW, Littner MR, Rowley JA, Gay P, Anderson WM, Hudgel DW, McEvoy RD, Loube DI. Home diagnosis of sleep apnea: a systematic review of the literature. An evidence review cosponsored by the American Academy of Sleep Medicine, the American College of Chest Physicians, and the American Thoracic Society. Chest 2003;124:15431579. 116. Sris F, Marc I, Cormier Y, La Forge J. Utility of nocturnal home oximetry for case finding in patients with suspected sleep apnea hypopnea syndrome. Ann Intern Med 1993;119:449453. 117. Andreu AL, Chiner E, Sancho-Chust JN, Pastor E, Llombart M, Gomez-Merino E, Senent C, Barb F. Effect of an ambulatory diagnostic and treatment program in patients with sleep apnoea. Eur Respir J 2012;39:305312.

118. Mulgrew AT, Fox N, Ayas NT, Ryan CF. Diagnosis and initial management of obstructive sleep apnea without polysomnography: a randomized validation study. Ann Intern Med 2007;146:157 166. 119. Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ, Hudgel D, Sateia M, Schwab R; Portable Monitoring Task Force of the American Academy of Sleep Medicine. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2007;3:737747. 120. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000;284:30153021. 121. Bucca CB, Brussino L, Battisti A, Mutani R, Rolla G, Mangiardi L, Cicolin A. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest 2007;132:440446. 122. Walsh JT, Andrews R, Starling R, Cowley AJ, Johnston ID, Kinnear WJ. Effects of captopril and oxygen on sleep apnoea in patients with mild to moderate congestive cardiac failure. Br Heart J 1995;73:237241. 123. Tamura A, Kawano Y, Kadota J. Carvedilol reduces the severity of central sleep apnea in chronic heart failure. Circ J 2009;73:295298. 124. Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 2007;50:417423. 125. Babu AR, Herdegen J, Fogelfeld L, Shott S, Mazzone T. Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. Arch Intern Med 2005;165:447 452. 126. Hassaballa HA, Tulaimat A, Herdegen JJ, Mokhlesi B. The effect of continuous positive airway pressure on glucose control in diabetic patients with severe obstructive sleep apnea. Sleep Breath 2005;9:176180. 127. Ohike Y, Kozaki K, Iijima K, Eto M, Kojima T, Ohga E, Santa T, Imai K, Hashimoto M, Yoshizumi M, Ouchi Y. Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressurepossible involvement of nitric oxide and asymmetric NG, NG-dimethylarginine. Circ J 2005;69:221226. 128. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med 2002;166:159165. 129. Mansfield DR, Gollogly NC, Kaye DM, Richardson M, Bergin P, Naughton MT. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med 2004;169:361366. 130. Kaneko Y, Floras JS, Usui K, Plante J, Tkacova R, Kubo T, Ando S, Bradley TD. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 2003;348:12331241. 131. Laaban JP, Pascal-Sebaoun S, Bloch E, Orvon-Frija E, Oppert JM, Huchon G. Left ventricular systolic dysfunction in patients with obstructive sleep apnea syndrome. Chest 2002;122:11331138. 132. Bradley TD, Logan AG, Kimoff RJ, Series F, Morrison D, Ferguson K, Belenkie I, Pfeifer M, Fleetham J, Hanly P, Smilovitch M, Tomlinson G, Floras JS; for the CANPAP Investigators. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005;353:20252033.

133. Arzt M, Wensel R, Montalvan S, Schichtl T, Schroll S, Budweiser S, Blumberg FC, Riegger GA, Pfeifer M. Effects of dynamic bilevel positive airway pressure support on central sleep apnea in men with heart failure. Chest 2008;134:6166. 134. Oldenburg O, Bitter T, Lehmann R, Korte S, Dimitriadis Z, Faber L, Schmidt A, Westerheide N, Horstkotte D. Adaptive servoventilation improves cardiac function and respiratory stability. Clin Res Cardiol 2011;100:107115. 135. Koyama T, Watanabe H, Kobukai Y, Makabe S, Munehisa Y, Iino K, Kosaka T, Ito H. Beneficial effects of adaptive servo ventilation in patients with chronic heart failure. Circ J 2010;74:21182124. 136. Kasai T, Usui Y, Yoshioka T, Yanagisawa N, Takata Y, Narui K, Yamaguchi T, Yamashina A, Momomura SI; JASV Investigators. Effect of flow-triggered adaptive servo-ventilation compared with continuous positive airway pressure in patients with chronic heart failure with coexisting obstructive sleep apnea and Cheyne-Stokes respiration. Circ Heart Fail 2010;3:140148. 137. Westhoff M, Arzt M, Litterst P. Influence of adaptive servoventilation on B-type natriuretic petide in patients with Cheyne-Stokes respiration and mild to moderate systolic and diastolic heart failure. Pneumologie 2010;64:467473. 138. Hastings PC, Vazir A, Meadows GE, Dayer M, Poole-Wilson PA, McIntyre HF, Morrell MJ, Cowie MR, Simonds AK. Adaptive servo-ventilation in heart failure patients with sleep apnea: a real world study. Int J Cardiol 2010;139:1724. 139. Teschler H, Dhring J, Wang YM, Berthon-Jones M. Adaptive pressure support servoventilation: a novel treatment for Cheyne-Stokes respiration in heart failure. Am J Respir Crit Care Med 2001;164:614619. 140. Bitter T, Westerheide N, Hossain MS, Lehmann R, Prinz C, Kleemeyer A, Horstkotte D, Oldenburg O. Complex sleep apnoea in congestive heart failure. Thorax 2011;66:402407. 141. Hanly PJ, Millar TW, Steljes DG, Baert R, Frais MA, Kryger MH. The effect of oxygen on respiration and sleep in patients with congestive heart failure. Ann Intern Med 1989;111:777782. 142. Franklin KA, Eriksson P, Sahlin C, Lundgren R. Reversal of central sleep apnea with oxygen. Chest 1997;111:163169. 143. Brostrm A, Hubbert L, Jakobsson P, Johansson P, Fridlund B, Dahlstrm U. Effects of longterm nocturnal oxygen treatment in patients with severe heart failure. J Cardiovasc Nurs 2005;20:385 396. 144. Phillips BA, Schmitt FA, Berry DT, Lamb DG, Amin M, Cook YR. Treatment of obstructive sleep apnea. A preliminary report comparing nasal CPAP to nasal oxygen in patients with mild OSA. Chest 1990;98:325330. 145. Puhan MA, Suarez A, Lo Cascio C, Zahn A, Heitz M, Braendli O. Didgeridoo playing as alternative treatment for obstructive sleep apnoea syndrome: randomised controlled trial. BMJ 2006;332:266270. 146. Ponikowski P, Javaheri S, Michalkiewicz D, Bart BA, Czarnecka D, Jastrzebski M, Kusiak A, Augostini R, Jagielski D, Witkowski T, Khayat RN, Oldenburg O, Gutleben KJ, Bitter T, Karim R, Iber C, Hasan A, Hibler K, Germany R, Abraham WT. Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure. Eur Heart J 2011. 147. Punjabi NM, Caffo BS, Goodwin JL, Gottlieb DJ, Newman AB, O'Connor GT, Rapoport DM, Redline S, Resnick HE, Robbins JA, Shahar E, Unruh ML, Samet JM. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 2009;6:e1000132. 148. Kapur V, Blough DK, Sandblom RE, Hert R, de Maine JB, Sullivan SD, Psaty BM. The medical cost of undiagnosed sleep apnea. Sleep 1999;22:749755.

Eur Heart J. 2013;34(11):809-815. 2013 Oxford University Press Copyright 2007 European Society of Cardiology. Published by Oxford University Press. All rights reserved.